VISTN Vistin Pharma ASA

Vistin Pharma ASA: Invitation to second quarter and first half results conference call

Vistin Pharma ASA: Invitation to second quarter and first half results conference call

Oslo, Norway, 21 August 2020

Vistin Pharma ASA will release its second quarter and first half 2020 results on Friday 28 August 2020. Vistin Pharma will host a conference call for all shareholders and interested parties on Friday 28 August at 08:30 CEST. There will be a Q&A session following the management discussion.

The conference call will be held in Norwegian.

The second quarter conference call will be available via web and audio through the following access points:

Telephone conference:

Confirmation Code:........ 9358318

International Dial-In:........ +44 (0) 2071 928338

Norway, Oslo:................

United States, New York:

Webcast:



*****



For further information, please contact:

Alexander Karlsen

CFO





EN
21/08/2020

Underlying

VISTNVistin Pharma ASA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vistin Pharma ASA

 PRESS RELEASE
Free
VISTN Vistin Pharma A...

Ex dividend NOK 1.25 today

Ex dividend NOK 1.25 today The shares in Vistin Pharma ASA (VISTN) will be traded ex dividend NOK 1.25 as from today, 04.06.2025.

June 4, 2025 1 EN
 PRESS RELEASE
Free
VISTN Vistin Pharma A...

Vistin Pharma ASA: Minutes from the annual general meeting 2025

Vistin Pharma ASA: Minutes from the annual general meeting 2025 Oslo, Norway, 22 May 2025 Vistin Pharma ASA (OSE: VISTN), please find attached the minutes from the annual general meeting held today, on the 22 May 2025. For further information, please contact: Alexander KarlsenCFO+47 97 05 36 21 This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachment

May 22, 2025 1 EN
 PRESS RELEASE
Free
VISTN Vistin Pharma A...

Disclosure of voting rights at AGM in Vistin Pharma ASA

Disclosure of voting rights at AGM in Vistin Pharma ASA Oslo, Norway, 22 May 2025 In relation to the Annual General Meeting in Vistin Pharma ASA (OSE: VISTN), on the 22th of May, the Company's Chair of the Board, Øyvin Brøymer, has received open proxies to represent a total of 5 156 012 shares in the Company at the AGM, corresponding to 11.63% of the total number of votes and shares in the Company. Together with the 14 509 280 shares held by Øyvin Brøymer through Intertrade Shipping AS, he will represent a total of 19 665 292 votes at the AGM, corresponding to a total of 44,35% of the tota...

May 22, 2025 1 EN
 PRESS RELEASE
Free
VISTN Vistin Pharma A...

Vistin Pharma ASA (VISTN): Update from the Election Committee

Vistin Pharma ASA (VISTN): Update from the Election Committee Oslo, Norway, 07 May 2025 The Election Committee has received a request from Øystein Stray Spetalen that he does not want to be re-elected as a board member of Vistin Pharma ASA. The Election Committee has therefore assessed the consequences of this for the recommendation submitted 13 March 2025 to this year's annual general meeting. Øystein Spetalen was the only board member up for election, and it was recommended that he was re-elected. The composition of the board's expertise has been assessed, and it has been investigated w...

May 7, 2025 1 EN
 PRESS RELEASE
Free
VISTN Vistin Pharma A...

Vistin Pharma ASA (VISTN): Mandatory notification of trade and disclos...

Vistin Pharma ASA (VISTN): Mandatory notification of trade and disclosure of large shareholding Ferncliff Listed Dai AS has on 6 May 2025 sold 1,234,280 shares in Vistin Pharma ASA at NOK 22.50 per share. Saga Pure ASA has on 6 May 2025 sold 700,000 shares in Vistin Pharma ASA at NOK 22.50 per share. After the transaction Saga Pure ASA and Ferncliff Listed Dai AS has no holding of shares in Vistin Pharma ASA. Øystein Stray Spetalen and associated parties have a holding of 331,886 shares in Vistin Pharma ASA. Saga Pure ASA and Ferncliff Listed Dai AS are closely associated with board mem...

May 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch